Advanced in Esophageal Cancer

Dr. Sarbajit K. Mukherjee

Oncology | Hematology
Baptist Health Medical Group Oncology LLC
8900 N Kendall Dr, 
Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Esophageal Cancer
Baptist Health Medical Group Oncology LLC
8900 N Kendall Dr, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sarbajit Mukherjee is an Oncologist and a Hematologist in Miami, Florida. Dr. Mukherjee is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Stomach Cancer, Colorectal Cancer, Esophageal Cancer, and Gastroesophageal Junction Cancer.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 20 articles in the study of Esophageal Cancer.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Baptist Hospital Of Miami
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

BAPTIST HEALTH MEDICAL GROUP ONCOLOGY LLC
8900 N Kendall Dr, Miami, FL 33176

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Other
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Enrollment Status: Completed
Publish Date: December 19, 2023
Intervention Type: Drug
Study Drugs: Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Study Phase: Phase 2
Phase 2a Study Evaluating a Chemokine-Modulatory Regimen in Patients With Colorectal Cancer Metastatic to the Liver
Phase 2a Study Evaluating a Chemokine-Modulatory Regimen in Patients With Colorectal Cancer Metastatic to the Liver
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Biological, Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

81 Total Publications

Effects of Neighborhood Deprivation Index on Survival in Gastroesophageal Adenocarcinoma.
Effects of Neighborhood Deprivation Index on Survival in Gastroesophageal Adenocarcinoma.
Journal: Healthcare (Basel, Switzerland)
Published: July 02, 2025
Similar Doctors
Vy T. Dinh
Advanced in Esophageal Cancer
Dr. Vy T. Dinh
Hematology Oncology | Hematology | Oncology
Advanced in Esophageal Cancer
Dr. Vy T. Dinh
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Oncology LLC

8900 N Kendall Dr, 
Miami, FL 
 (0.1 miles away)
786-596-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vy Dinh is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Dinh is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. Her top areas of expertise are Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Dubin-Johnson Syndrome, and Lung Adenocarcinoma. Dr. Dinh is currently accepting new patients.

Advanced in Esophageal Cancer
Dr. Warren S. Brenner
Oncology | Hematology
Advanced in Esophageal Cancer
Dr. Warren S. Brenner
Oncology | Hematology

Brrh Oncology, LLC

6282 Linton Blvd, 
Delray Beach, FL 
 (53.6 miles away)
561-495-8307
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Warren Brenner is an Oncologist and a Hematologist in Delray Beach, Florida. Dr. Brenner is rated as a Distinguished provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Anal Cancer, and Familial Colorectal Cancer. Dr. Brenner is currently accepting new patients.

Experienced in Esophageal Cancer
Dr. Gustavo A. Cadavid
Hematology Oncology | Hematology | Oncology
Experienced in Esophageal Cancer
Dr. Gustavo A. Cadavid
Hematology Oncology | Hematology | Oncology

Oncology And Radiation Associates, PA

3659 S Miami Ave, Suite 2001, 
Miami, FL 
 (8.8 miles away)
305-854-8801
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Gustavo Cadavid is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Cadavid is rated as a Distinguished provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Thrombocytopenia, and Drug-Induced Thrombocytopenia. Dr. Cadavid is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mukherjee's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile